Analyst ratings often influence investor sentiment and can impact a company's stock price. In this case, the majority of analysts have given Corcept Therapeutics a bullish rating, which could lead to increased investor confidence and a potential rise in the stock price. Additionally, the increase in the average 12-month price target suggests that analysts expect the company's stock price to rise in the future.